PRODUCTS & SERVICES
Custom Oligonucleotides Services
From more than 100 worldwide applicants, only 11 startups were selected for the second batch of Health Hub Vienna (HHV), a three-month intensive acceleration program. This batch is multinational, featuring participants from the USA, UK, Sweden, Israel, Belarus, Slovakia, Germany, and only 3 from Austria.
HHV is a platform for healthcare stakeholders who share a common vision: To change the healthcare system through innovation and entrepreneurship. To fulfill this goal, HHV supports biotech and medtech startups through an acceleration program, managed by INiTS—Vienna's leading high-tech incubator with a focus on life sciences. Today’s startups have a particularly difficult time in the healthcare sector. They are required to endure long testing periods and have more financial reserves than in other industries. Selling new technology is also a challenge, as the healthcare standards vary greatly from country to country. The aim of HHV is to speed up innovation, that these startups may overcome these difficult conditions.
Dr. Pavol Cekan, Founder and CEO of MultiplexDX, comments:
"Health Hub Vienna is one of the top 3 accelerators in Europe. Of course, it's an amazing opportunity for us to participate in this program and meet the industry’s best experts, mentors, investors, advisors, etc. It's a unique chance to get a new insight, upgrade our business model, build a powerful network, and progress much more quickly!"
In general, the HHV accelerator program is about new ideas, future challenges, driving transformations in healthcare, high-impact business models, regulations and certifications, investment strategies, and how to scale-up one’s business. The program ends 29 November, with the last two days focused on solidifying the opportunities discussed during the previous week’s one-on-one meetings. The HHV team strives to connect startups with new, important contacts identified during the preceding sessions.
The Health Hub Vienna sees itself as a platform for innovation in healthcare. There, pharmaceutical companies, medical device manufacturers, private and public insurers and startups work together on the latest innovations. The goal is to improve medical care. Together with partners such as the MedUni Vienna, UNIQA and INiTS – with the Vienna University Founder Service, they have launched a program that supports young companies in the healthcare sector. For three months, they offer workshops and link them with key partners in the industry.
"The philosophy of Health Hub Vienna is to change the world of healthcare. This change-for-the-better can only succeed when all parties learn and work together."
says Irene Fialka, CEO of INiTS
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.